Literature DB >> 28334808

Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy.

Goo-Young Kim1, Joon Hyun Kwon1, Jun-Ho Cho1, Lisa Zhang1, Brian C Mansfield1,2, Janice Y Chou1.   

Abstract

Glycogen storage disease type Ia (GSD-Ia) is characterized by impaired glucose homeostasis and long-term risks of hepatocellular adenoma (HCA) and carcinoma (HCC). We have shown that the non-tumor-bearing (NT), recombinant adeno-associated virus (rAAV) vector-treated GSD-Ia mice (AAV-NT mice) expressing a wide range (0.9-63%) of normal hepatic glucose-6-phosphatase-α activity maintain glucose homeostasis and display physiologic features mimicking animals living under calorie restriction (CR). We now show that in AAV-NT mice, the signaling pathways of the CR mediators, AMP-activated protein kinase (AMPK) and sirtuin-1 are activated. AMPK/sirtuin-1 inhibit the activity of STAT3 (signal transducer and activator of transcription 3) and NFκB (nuclear factor κB), the pro-inflammatory and cancer-promoting transcription factors. Sirtuin-1 also inhibits cancer metastasis via increasing the expression of E-cadherin, a tumor suppressor, and decreasing the expression of mesenchymal markers. Consistently, in AAV-NT mice, hepatic levels of active STAT3 and NFκB-p65 were reduced as were expression of mesenchymal markers, STAT3 targets, NFκB targets and β-catenin targets, all of which were consistent with the promotion of tumorigenesis. AAV-NT mice also expressed increased levels of E-cadherin and fibroblast growth factor 21 (FGF21), targets of sirtuin-1, and β-klotho, which can acts as a tumor suppressor. Importantly, treating AAV-NT mice with a sirtuin-1 inhibitor markedly reversed many of the observed anti-inflammatory/anti-tumorigenic signaling pathways. In summary, activation of hepatic AMPK/sirtuin-1 and FGF21/β-klotho signaling pathways combined with down-regulation of STAT3/NFκB-mediated inflammatory and tumorigenic signaling pathways can explain the absence of hepatic tumors in AAV-NT mice. Published by Oxford University Press 2017. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28334808      PMCID: PMC6075378          DOI: 10.1093/hmg/ddx097

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  40 in total

1.  Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I).

Authors:  Jan Peter Rake; Gepke Visser; Philippe Labrune; James V Leonard; Kurt Ullrich; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2002-08-22       Impact factor: 3.183

Review 2.  Understanding the Physiology of FGF21.

Authors:  Ffolliott Martin Fisher; Eleftheria Maratos-Flier
Journal:  Annu Rev Physiol       Date:  2015-11-19       Impact factor: 19.318

3.  Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.

Authors:  Goo-Young Kim; Young Mok Lee; Joon Hyun Kwon; Jun-Ho Cho; Chi-Jiunn Pan; Matthew F Starost; Brian C Mansfield; Janice Y Chou
Journal:  Mol Genet Metab       Date:  2017-01-10       Impact factor: 4.797

Review 4.  Mutations leading to constitutive active gp130/JAK1/STAT3 pathway.

Authors:  Camilla Pilati; Jessica Zucman-Rossi
Journal:  Cytokine Growth Factor Rev       Date:  2015-07-03       Impact factor: 7.638

5.  Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction.

Authors:  Justin A Fletcher; Grace M Meers; M Harold Laughlin; Jamal A Ibdah; John P Thyfault; R Scott Rector
Journal:  Appl Physiol Nutr Metab       Date:  2012-08-15       Impact factor: 2.665

Review 6.  Nitric oxide in liver diseases.

Authors:  Yasuko Iwakiri; Moon Young Kim
Journal:  Trends Pharmacol Sci       Date:  2015-05-28       Impact factor: 14.819

7.  Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.

Authors:  Julien Calderaro; Philippe Labrune; Guillaume Morcrette; Sandra Rebouissou; Dominique Franco; Sophie Prévot; Alberto Quaglia; Pierre Bedossa; Louis Libbrecht; Luigi Terracciano; G Peter A Smit; Paulette Bioulac-Sage; Jessica Zucman-Rossi
Journal:  J Hepatol       Date:  2012-10-06       Impact factor: 25.083

Review 8.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 9.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer.

Authors:  Mousumi Tania; Md Asaduzzaman Khan; Junjiang Fu
Journal:  Tumour Biol       Date:  2014-06-02

10.  Ex-527 inhibits Sirtuins by exploiting their unique NAD+-dependent deacetylation mechanism.

Authors:  Melanie Gertz; Frank Fischer; Giang Thi Tuyet Nguyen; Mahadevan Lakshminarasimhan; Mike Schutkowski; Michael Weyand; Clemens Steegborn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-09       Impact factor: 11.205

View more
  8 in total

Review 1.  Gene therapy for glycogen storage diseases.

Authors:  Priya S Kishnani; Baodong Sun; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

2.  Response letter.

Authors:  Youngmok Lee; Janice Y Chou; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2018-11       Impact factor: 4.982

Review 3.  FGF21 in obesity and cancer: New insights.

Authors:  Weiqin Lu; Xiaokun Li; Yongde Luo
Journal:  Cancer Lett       Date:  2020-11-29       Impact factor: 8.679

Review 4.  Biomarkers in Glycogen Storage Diseases: An Update.

Authors:  Alberto Molares-Vila; Alberte Corbalán-Rivas; Miguel Carnero-Gregorio; José Luís González-Cespón; Carmen Rodríguez-Cerdeira
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

5.  Quercetin Regulates Key Components of the Cellular Microenvironment during Early Hepatocarcinogenesis.

Authors:  Itayetzi Reyes-Avendaño; Edilburga Reyes-Jiménez; Karina González-García; Dulce Carolina Pérez-Figueroa; Rafael Baltiérrez-Hoyos; Gabriela Tapia-Pastrana; Xariss Miryam Sánchez-Chino; Saúl Villa-Treviño; Jaime Arellanes-Robledo; Verónica Rocío Vásquez-Garzón
Journal:  Antioxidants (Basel)       Date:  2022-02-11

6.  Ameliorating Inflammation in Insulin-resistant Rat Adipose Tissue with Abdominal Massage Regulates SIRT1/NF-κB Signaling.

Authors:  Tianjiao Gao; Shaotao Chen; Yiran Han; Dongmei Zhang; Yi Tan; Yutao He; Mingjun Liu
Journal:  Cell Biochem Biophys       Date:  2022-07-30       Impact factor: 2.989

7.  Spontaneous Occurrence of Various Types of Hepatocellular Adenoma in the Livers of Metabolic Syndrome-Associated Steatohepatitis Model TSOD Mice.

Authors:  Wenhua Shao; Orgil Jargalsaikhan; Mayuko Ichimura-Shimizu; Qinyi Cai; Hirohisa Ogawa; Yuko Miyakami; Kengo Atsumi; Mitsuru Tomita; Mitsuko Sutoh; Shunji Toyohara; Ryoji Hokao; Yasusei Kudo; Takeshi Oya; Koichi Tsuneyama
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

8.  Predominance of the c.648G > T G6PC gene mutation and late complications in Korean patients with glycogen storage disease type Ia.

Authors:  Yoo-Mi Kim; Jin-Ho Choi; Beom-Hee Lee; Gu-Hwan Kim; Kyung-Mo Kim; Han-Wook Yoo
Journal:  Orphanet J Rare Dis       Date:  2020-02-11       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.